ALT5 Sigma Corp Files 8-K, Reports Other Events
Ticker: ALTS · Form: 8-K · Filed: Nov 26, 2024 · CIK: 862861
Sentiment: neutral
Topics: corporate-action, filing-update, financials
TL;DR
ALT5 Sigma Corp (formerly JanOne) filed an 8-K on Nov 19th, check for financial updates.
AI Summary
ALT5 Sigma Corporation, formerly JanOne Inc., filed an 8-K on November 26, 2024, reporting an event on November 19, 2024. The filing indicates a change in the company's reporting status and includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Las Vegas, NV.
Why It Matters
This 8-K filing signals a significant update from ALT5 Sigma Corp, potentially related to its financial status or operational events, which is crucial for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate indication of significant negative developments.
Key Numbers
- 000-19621 — SEC File Number (Identifies the company's filing history with the SEC.)
- 41-1454591 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ALT5 Sigma Corporation (company) — Registrant
- JanOne Inc. (company) — Former Name
- November 19, 2024 (date) — Earliest event reported
- November 26, 2024 (date) — Filing date
- 325 E. Warm Springs Road, Suite 102, Las Vegas, NV 89119 (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by ALT5 Sigma Corporation on November 19, 2024?
The filing indicates 'Other Events' as an item of information but does not detail the specific events within the provided text.
What is the significance of the former company name 'JanOne Inc.'?
ALT5 Sigma Corporation was formerly known as JanOne Inc., indicating a name change occurred prior to this filing.
Where are ALT5 Sigma Corporation's principal executive offices located?
The principal executive offices are located at 325 E. Warm Springs Road, Suite 102, Las Vegas, NV 89119.
What is the SIC code for ALT5 Sigma Corporation?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was ALT5 Sigma Corporation incorporated?
The company is incorporated in Nevada.
Filing Stats: 701 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-11-26 12:55:47
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ALTS The NASDAQ Sto
Filing Documents
- jan-20241119.htm (8-K) — 27KB
- exh10118_alyea-soinbioxter.htm (EX-10.118) — 35KB
- image_0.jpg (GRAPHIC) — 11KB
- image_1.jpg (GRAPHIC) — 38KB
- image_2.jpg (GRAPHIC) — 32KB
- 0001628280-24-049241.txt ( ) — 308KB
- jan-20241119.xsd (EX-101.SCH) — 2KB
- jan-20241119_lab.xml (EX-101.LAB) — 23KB
- jan-20241119_pre.xml (EX-101.PRE) — 13KB
- jan-20241119_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events . On November 19, 2024, ALT5 Sigma Corporation ("ALT5") signed a non-binding term sheet with Dr. Amol Soin, sole member of Soin Bioscience LLC ("Soin Bio"), a pharmaceutical development company ("Soin Bio"), relating to the proposed acquisition of Soin Bio by Alyea Therapeutics Corporation ("Alyea"), a wholly-owned subsidiary of ALT5. This acquisition would be part of Alyea's pipeline for pain management pharmaceutical development. ALT5 had previously announced plans to separate its biotech business from its fintech business in the first half of 2025. The proposed acquisition, which includes Soin Bio's innovative "clear patch" pain medication technology, will support Alyea's mission to become a leader in the development of non-addictive pain medications. Soin Bio's clear patch technology is designed to be applied to any area of pain, similar to a gel, which then dries to function as a pain patch. It is designed to provide continuous delivery of pain medication for up to eight hours, allowing for customized treatment over the targeted area. Unlike conventional pain patches, Soin Bio's patch is clear, invisible, and can be applied over difficult areas, such as joints or body creases. Additionally, it is not water-soluble, ensuring it remains effective even if the area becomes moist. The Soin Bio clear patch technology is still in the investigational stage and is pending clinical trials before FDA approval and market launch. The letter of intent is the first step in the anticipated acquisition process. The closing of the transaction is subject to a satisfactory due diligence review, tax-related structuring, the preparation and execution of definitive acquisition agreements, and other usual and customary closing conditions for transactions of this scope and magnitude. Section 9 – Financial Statements and Exhibits
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.118 Non-binding Term Sheet between Alyea Technologies Corporation and Soin Bioscience LLC, dated November 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALT5 Sigma Corporation By: /s/ Peter Tassiopoulos Name: Peter Tassiopoulos Title: Chief Executive Officer Dated: November 26, 2024